Fulton Bank Decreased Its Hanesbrands (HBI) Holding; 8 Analysts Bullish Cymabay Therapeutics, Inc. (CBAY)

Among 8 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 25 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Wednesday, March 21 by Oppenheimer. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Piper Jaffray on Monday, July 17. H.C. Wainwright upgraded the shares of CBAY in report on Monday, January 30 to “Buy” rating. On Tuesday, November 28 the stock rating was maintained by Leerink Swann with “Buy”. The firm earned “Buy” rating on Thursday, January 25 by Roth Capital. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Tuesday, September 19 by Cantor Fitzgerald. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, July 25 report. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, January 31 with “Buy” rating. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Overweight” rating by Piper Jaffray on Tuesday, July 21. H.C. Wainwright downgraded the shares of CBAY in report on Wednesday, June 1 to “Neutral” rating. See Cymabay Therapeutics, Inc. (NASDAQ:CBAY) latest ratings:

21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: SunTrust Rating: Buy New Target: $19.0 Maintain
16/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $16.0 Maintain
13/02/2018 Broker: Evercore Rating: Outperform Initiates Coverage On
31/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $15.0 Maintain
25/01/2018 Broker: Roth Capital Rating: Buy New Target: $27.0 Initiate
24/01/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $12 New Target: $18 Maintain
10/01/2018 Broker: Oppenheimer Rating: Buy New Target: $15.0 Maintain
28/11/2017 Broker: Leerink Swann Rating: Buy New Target: $16.0 Maintain

Fulton Bank decreased Hanesbrands Inc (HBI) stake by 20.13% reported in 2017Q3 SEC filing. Fulton Bank sold 13,892 shares as Hanesbrands Inc (HBI)’s stock declined 1.43%. The Fulton Bank holds 55,123 shares with $1.36M value, down from 69,015 last quarter. Hanesbrands Inc now has $6.70 billion valuation. The stock decreased 2.11% or $0.4 during the last trading session, reaching $18.59. About 4.39M shares traded. Hanesbrands Inc. (NYSE:HBI) has declined 23.23% since March 23, 2017 and is downtrending. It has underperformed by 39.93% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $746.48 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

The stock decreased 5.13% or $0.69 during the last trading session, reaching $12.76. About 558,431 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since March 23, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Among 19 analysts covering Hanesbrands (NYSE:HBI), 10 have Buy rating, 0 Sell and 9 Hold. Therefore 53% are positive. Hanesbrands has $42 highest and $20 lowest target. $25.72’s average target is 38.35% above currents $18.59 stock price. Hanesbrands had 58 analyst reports since September 17, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 4 by Citigroup. The rating was maintained by Citigroup on Friday, February 9 with “Neutral”. The stock of Hanesbrands Inc. (NYSE:HBI) has “Buy” rating given on Thursday, November 2 by Buckingham Research. FBR Capital maintained it with “Buy” rating and $30.0 target in Thursday, February 8 report. The firm earned “Neutral” rating on Tuesday, December 19 by Citigroup. The rating was reinitiated by Buckingham Research on Monday, July 17 with “Buy”. As per Friday, February 9, the company rating was maintained by Deutsche Bank. The rating was upgraded by Goldman Sachs on Friday, December 4 to “Conviction Buy”. The firm has “Buy” rating by B. Riley & Co given on Friday, February 9. On Thursday, August 24 the stock rating was maintained by Cowen & Co with “Hold”.

Fulton Bank increased Vanguard Index Fds (VVIAX) stake by 51,440 shares to 451,075 valued at $17.57M in 2017Q3. It also upped Harding Loevner Fds Inc stake by 16,792 shares and now owns 147,644 shares. Vanguard Index Fds (VFIAX) was raised too.

Since February 15, 2018, it had 0 buys, and 1 sale for $1.07 million activity. $1.07M worth of Hanesbrands Inc. (NYSE:HBI) shares were sold by Upchurch W Howard Jr.

Analysts await Hanesbrands Inc. (NYSE:HBI) to report earnings on May, 1. They expect $0.24 earnings per share, down 17.24% or $0.05 from last year’s $0.29 per share. HBI’s profit will be $86.49 million for 19.36 P/E if the $0.24 EPS becomes a reality. After $0.52 actual earnings per share reported by Hanesbrands Inc. for the previous quarter, Wall Street now forecasts -53.85% negative EPS growth.